Tenet Healthcare Corporation
268.45USD
-2.1800 (-0.81%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on THC.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $4.68▲ | $4.09 | 1 | 1 |
| Next quarter | $5.67▲ | $4.73 | 0 | 1 |
| Current year | $21.23▲ | $17.85 | 0 | 1 |
| Next year | $21.09▲ | $17.79 | 0 | 1 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $4.26 | $6.12 | +1.86 (+43.5%) |
| 2026-03-31 | $4.17 | $4.82 | +0.65 (+15.7%) |
| 2025-12-31 | $4.07 | $4.7 | +0.63 (+15.6%) |
| 2025-09-30 | $3.35 | $3.7 | +0.35 (+10.5%) |
369 ratings from 36 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $283 $307 | Oct 16, 2026 |
| BMO Capital | Initiated | Market Perform | $265 | Sep 23, 2026 |
| Leerink Partners | Maintained | Outperform | $309 | Sep 18, 2026 |
| Wells Fargo | Maintained | Overweight | $231 $281 | Aug 3, 2026 |
| Truist Securities | Maintained | Buy | $270 $290 | Jul 28, 2026 |
| Baird | Maintained | Neutral | $210 $280 | Jul 28, 2026 |
| Guggenheim | Maintained | Buy | $242 $283 | Jul 28, 2026 |
| UBS | Maintained | Buy | $288 $308 | Jul 27, 2026 |
| TD Cowen | Maintained | Buy | $233 $263 | Jul 27, 2026 |
| Morgan Stanley | Maintained | Overweight | $254 $274 | Jul 27, 2026 |
| RBC Capital | Maintained | Outperform | $236 $283 | Jul 27, 2026 |
| Barclays | Maintained | Overweight | $240 $271 | Jul 24, 2026 |
| Guggenheim | Maintained | Buy | $252 $242 | Jul 20, 2026 |
| Wells Fargo | Maintained | Overweight | $213 $231 | Jul 13, 2026 |
| Barclays | Maintained | Overweight | $238 $240 | Jul 9, 2026 |
| TD Cowen | Maintained | Buy | $242 $233 | Jun 22, 2026 |
| Barclays | Maintained | Overweight | $257 $238 | May 5, 2026 |
| Baird | Maintained | Neutral | $245 $210 | May 5, 2026 |
| Stephens & Co. | Maintained | Overweight | $275 $260 | May 4, 2026 |
| RBC Capital | Maintained | Outperform | $277 $236 | May 1, 2026 |
| Guggenheim | Maintained | Buy | $283 $252 | May 1, 2026 |
| Wells Fargo | Maintained | Overweight | $265 $213 | May 1, 2026 |
| Keybanc | Maintained | Overweight | $250 $225 | May 1, 2026 |
| Guggenheim | Maintained | Buy | $271 $283 | Mar 12, 2026 |
| Mizuho | Maintained | Outperform | $235 $265 | Mar 12, 2026 |
108 filings from 22 insiders · 12 buy / 14 sell over 6m
Officers and directors of THC, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KERREY J ROBERTDirector | Sell | 2.5k | $264.62 | $662k | Sep 14, 2026 |
| KERREY J ROBERTDirector | Sell | 4.0k | $264.10 | $1.06M | Sep 14, 2026 |
| KERREY J ROBERTDirector | Sell | 5.5k | $263.04 | $1.44M | Sep 14, 2026 |
| MARK RICHARD JDirector | Sell | 10.0k | $263.42 | $2.63M | Sep 10, 2026 |
| West NadjaDirector | Sell | 1.2k | $258.80 | $298k | Sep 2, 2026 |
| Foo Lisa YOfficer, EVP, Chief Operating Officer | Sell | 24.0k | $266.32 | $6.39M | Aug 31, 2026 |
| HANEY CECIL DDirector | Gift | 150 | — | — | Aug 28, 2026 |
| SUTARIA SAUMYAChief Executive Officer | Sell | 100.0k | $273.34 | $27.64M | Aug 25, 2026 |
| HANEY CECIL D.Director | Sell | 1.3k | $278.03 | $361k | Aug 24, 2026 |
| ROMO TAMMYDirector | Sell | 7.4k | $260.83 | $1.95M | Aug 7, 2026 |
| BLUNT ROYDirector | Sell | 600 | $262.68 | $158k | Aug 5, 2026 |
| FOO LISA YChief Operating Officer | Sell | 10.0k | $258.03 | $2.58M | Jul 29, 2026 |
| LYNCH CHRISTOPHER SDirector | Sell | 3.8k | $243.44 | $934k | Jul 27, 2026 |
| BIERMAN JAMES LDirector | Sell | 5.0k | $244.96 | $1.22M | Jul 27, 2026 |
| ARBOUR PAOLA MChief Technology Officer | Sell | 10.9k | $243.90 | $2.65M | Jul 27, 2026 |
| KERREY JOSEPH ROBERTDirector | Sell | 5.6k | $173.12 | $984k | May 28, 2026 |
| WEST NADJA Y.Director | Sell | 3.0k | $177.35 | $532k | May 27, 2026 |
| FITZGERALD MEGHANDirector | Other | 1.3k | — | — | May 22, 2026 |
| LYNCH CHRISTOPHER SDirector | Other | 1.3k | — | — | May 22, 2026 |
| WEST NADJA Y.Director | Other | 1.3k | — | — | May 22, 2026 |
Members whose judged calls on THC have played out most reliably.
No settled calls on THC yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
22 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 14 | 4 | 0 | 0 | Buy1.96 |
| 1 mo ago | 5 | 14 | 4 | 0 | 0 | Buy1.96 |
| 2 mo ago | 5 | 14 | 3 | 0 | 0 | Buy1.91 |
| 3 mo ago | 5 | 14 | 3 | 0 | 0 | Buy1.91 |